Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129675 · ClinicalTrials.gov registry record · Phase 2
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
A Phase 2 study of Parkinsonian Syndrome, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
- 1
- Study location
NCT00129675 is a Phase 2 study of Parkinsonian Syndrome that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 169 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00129675, a Phase 2 study of Parkinsonian Syndrome, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parkinsonian syndrome (PS) is suspected, but the diagnosis remains unclear from a clinical standpoint.
Conditions Studied
Interventions
- DRUG [123I]ß CIT
Study Locations (1)
Connecticut
- Institute for Neurodegenerative Disorders - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129675
The ClinicalTrials.gov registry entry for NCT00129675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinsonian Syndrome appearing as the primary indexed condition, and to 1 intervention - of which [123I]ß CIT is the first listed.
NCT00129675 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00129675 about?
NCT00129675 is a clinical study titled "Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty". The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parkinsonian syndrome (PS) is suspected, but the diagnosis remains unclear from a clinical standpoint.
What is the current status of trial NCT00129675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2003-02. Estimated completion is 2009-05.
What conditions does trial NCT00129675 study?
This clinical trial studies the following conditions: Parkinsonian Syndrome.
What interventions are being tested in trial NCT00129675?
The interventions under investigation include: [123I]ß CIT (DRUG).
Who is sponsoring clinical trial NCT00129675?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00129675 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsonian Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.